RDHL Redhill Biopharma Ltd.

9.88
+0.07  (0.71%)
Previous Close 9.81
Open 9.66
Price To book 3.08
Market Cap 125.94M
Shares 12,747,000
Volume 71,246
Short Ratio 1.87
Av. Daily Volume 68,606

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b to be initiated 1H 2017.
YELIVA
Prevention of mucositis in cancer patients undergoing therapeutic radiotherapy
Phase 1/2 trial initiation announced September 8, 2016. Announced that dosing has commenced - December 19, 2016.
YELIVA
Refractory or relapsed multiple myeloma - cancer
Planned resubmission of NDA due 1H 2017.
RIZAPORT (RHB-103)
Migraine
Phase 3 DSMB safety analysis released December 13, 2016 - trial to continue as planned. Interim efficacy analysis due 2Q 2017.
RHB-104 MAP US
Crohn’s disease
Phase 3 final data released March 2016. Additional Phase 3 trial planned to be initiated by April 2017.
RHB-105
H. pylori
Phase 3 enrollment of final patient announced February 13, 2017 with top-line data due 2Q 2017.
BEKINDA -GUARD
Gastroenteritis
Phase 2a data released December 12, 2016.
RHB-104 CEASE-MS
Multiple sclerosis
Phase 2 top-line data due mid 2017.
BEKINDA
IBS-D
Phase 2 initiated October 2016.
YELIVA
Hepatocellular carcinoma (HCC) - cancer
Phase 2 to be initiated 2H 2016
YELIVA
Mucositis in cancer patients
Phase 1/2 trial amended to include Kaposi sarcoma patients. Trial due to resume in late 2016.
YELIVA
Refractory/relapsed diffuse large B-cell lymphoma (DLBCL)

Latest News

  1. 8:04 am RedHill Biopharma completes treatment of last patient in BEKINDA Phase III study for Acute Gastroenteritis; top-line results are expected in 2Q17
  2. RedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis
  3. RedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis
  4. RedHill Biopharma to Host Fourth Quarter and Full-Year 2016 Financial Results Conference Call on February 23, 2017
  5. RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis
  6. RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis
  7. The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
  8. 4 Drug Stocks that are Broker Favorites
  9. RedHill Biopharma to Present at the BIO CEO & Investor Conference
  10. The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma
  11. Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?
  12. Blog Coverage Redhill Receives QIDP Fast-Track Designation from FDA for its Nontuberculous Mycobacteria Infections Combination Therapy
  13. RedHill Biopharma Provides 2017 Semi-Annual Business Update
  14. RedHill Biopharma Provides 2017 Semi-Annual Business Update
  15. RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections
  16. RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections
  17. RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection
  18. RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection
  19. RedHill Biopharma’s RHB-105 Positive Phase III Study Results for H. pylori Infection Presented at the Innovations in Gastroenterology 2017 Symposium
  20. RedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management